Navigation Links
Acceleron Pharma's ACE-031 Increases Muscle Mass and Strength in,Preclinical Studies

LUCCA, Italy--(BUSINESS WIRE)--May 14, 2007 - Acceleron Pharma, Inc., a biopharmaceutical company developing therapeutics for the treatment of musculoskeletal, metabolic and cancer-related diseases, today announced results of a preclinical study with ACE-031 that demonstrated the ability of the compound to increase muscle mass and strength in normal mice and in murine models of muscular dystrophy. ACE-031 inhibits negative regulators of muscle to increase muscle mass and strength as a potential treatment for neuromuscular diseases and cancer-related muscle loss. The data was presented on Sunday, May 13 at the Gordon Research Conference on Myogenesis in Lucca, Italy.

"Acceleron is encouraged by the significant outcomes and positive data generated by ACE-031 spanning numerous preclinical models of muscle loss", said Jas Seehra, Ph.D., Chief Scientific Officer of Acceleron. "ACE-031 and related Acceleron compounds consistently demonstrate substantial increases in skeletal muscle mass and strength."

ACE-031, a protein therapeutic based on the activin receptor type IIB (ActRIIB), is the first of several compounds Acceleron is developing for the treatment of diseases involving the loss of muscle mass, strength and function. ActRIIB binds to myostatin (GDF-8) and other negative regulators of muscle mass and strength. Over-expression of myostatin has been shown to cause a loss in muscle mass and strength, and inhibition of myostatin results in the selective increase in skeletal muscle mass and strength. In preclinical models, ACE-031 increased skeletal muscle mass and strength in disease models of amyotrophic lateral sclerosis (ALS), muscular dystrophy, glucocorticoid-induced muscle loss and age-related muscle loss (sarcopenia). ACE-031 offers the potential for an entirely new type of therapy for the treatment of various muscle wasting conditions.

"The clinical potential of ACE-031 to selectively increase
'"/>




Page: 1 2 3

Related medicine technology :

1. Accelreon Pharmas ACE-031Shown to Increase Muscle Mass in Preclinical Studies
2. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
3. Rapid HIV Testing Increases Possibility of Treatment
4. ProtoKinetixs AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells
5. MabThera Significantly Increases Survival of Lymphoma Patients Regardless of Chemotherapy Regimen
6. Researchers Discover a Common Variation in a Gene Segment that Increases the Risk for Prostate Cancer
7. New Data on Market-Leading Velcade (Bortezomib) for Injection Further Strengthen Role in Previously Treated Multiple Myeloma
8. SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems
9. EntreMeds Aurora Kinase Inhibitor Induces Tumor Regression in Preclinical Models
10. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
11. Data Presented at AACR Meeting Shows Bavituximab Equivalent Plus Docetaxel Reduces Growth of Both Hormone-Dependent and Hormone-Independent Prostate Cancer by Up to 94 Percent in Preclinical Studies
Post Your Comments:
(Date:6/29/2015)... SAN FRANCISCO , June 29, ... company,s novel blood-draw technology has received CE Mark ... quality from the European Union. This regulatory milestone ... alternative to one of the most common procedures ... Velano Vascular,s proprietary device reduces the ...
(Date:6/29/2015)... , June 29, 2015 ... and predicted revenues ,Where is the market for dermatological ... market? Visiongain ,s new report shows you potential ... and prospects. Our 310 page report ... most lucrative areas in the industry and the future ...
(Date:6/29/2015)... Calif. , June 29, 2015  The ... innovative features to cars on the basis of ... The industry is now on the verge of ... cars. While automotive HWW non-critical features such as ... be present in 30 to 40 percent of ...
Breaking Medicine Technology:Velano Vascular Receives CE Mark For Novel Blood Draw Technology Designed to Reduce Needle Exposures for Hospitalized Patients and Healthcare Providers 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 2Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 3Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 4Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 5Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 6Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 7Dermatological Drugs Market Forecast 2015-2025 Opportunities for Leading Companies 8Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 2Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 3Convergence Trends See the Automotive Industry Integrate Health, Wellness and Wellbeing into Vehicles 4
... Expected in November 2008, BOTHELL, Wash., Oct. 9 ... the completion of patient enrollment and dosing,for the third ... and,efficacy of its formulation of 12-hour extended-release (ER) ibuprofen ... top-line,results from this pivotal trial in November 2008. Ibuprofen ...
... Will Reduce Animal Use in Cosmetics and Chemicals ... Corp. today announced,that results of a recently completed ... EpiDerm in vitro human skin tissue,equivalent. The test ... to be accepted as a validated alternative to ...
Cached Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3MatTek's EpiDerm In Vitro Tissues Headed for Validation in Europe 2
(Date:6/29/2015)... New York (PRWEB) , ... June 29, 2015 ... ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against C.R. Bard, Inc. and Ethicon, Inc. ... court documents, the proceedings’ next Case Management Conference is to be convened on ...
(Date:6/29/2015)... Valley, CA (PRWEB) , ... June 29, 2015 , ... ... treatments designed to lift and tighten sagging skin. Ulthera is a special treatment that ... Instead, it uses ultrasound technology to gently stimulate collagen production. Ulthera is highly targeted ...
(Date:6/29/2015)... ... June 29, 2015 , ... Bionops Laboratories has released the ... French consumers. , The specialized eye health formulation contains a variety of ingredients ... In addition to Citicoline (Cognizin®), Biomacula provides necessary doses of Vitamin E, Glutathione, ...
(Date:6/29/2015)... ... June 29, 2015 , ... Blue Cross ... leaders with the Commercial Markets division, which includes the company’s commercial health plan ... companies with regional, national and international reach. Mary Ellen Anderson now holds the ...
(Date:6/29/2015)... ... June 29, 2015 , ... ... informed, responsible and legal access to Health Canada's medical cannabis program, today officially ... education on how Health Canada's medical marijuana system works. Members are connected with ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 2Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 3Health News:Transvaginal Mesh Lawsuit News: New Jersey Court Overseeing Thousands of Ethicon, C.R. Bard Pelvic Mesh Claims Schedules July Conference 4Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 2Health News:Dermatologist, Dr. Peyman Ghasri, is Now Offering Non-Invasive Skin Tightening Procedures 3Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 2Health News:Bionops Laboratory Releases Biomacula, the First French Product with Citicoline (Cognizin®) 3Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 2Health News:Blue Cross and Blue Shield of Minnesota announces two new leadership appointments within its Commercial Markets division 3Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 2Health News:National Access Cannabis Opens Flagship Ottawa Care Centre 3
... Macpherson, the Australian model says that she had a lot of ... appreciate her "amazing body" //. ,Macpherson hated her tall figure ... says, "I have to say I had an amazing body and ... I felt so Amazonian and it wasn't really fashionable at the ...
... that patients on medications for blood pressure and cholesterol ... can now safely consume grapefruit juice- which has lot ... juice for some was due to some studies that ... dangerous side effects. ,The answer has been found by ...
... Day, India’s premier retail chain of coffee cafes, on opening its ... to reach the target of 500 by the year 2007. // ... are very happy to have played a large role in firmly ... director of the Amalgamated Bean Coffee Trading Company Ltd., the parent ...
... has been documented in Acute Coronary Syndrome patients, instituted ... the Society for Cardiovascular Angiography and Interventions (SCAI) // ... ,By combining data from nine randomized clinical trials ... the analysis was able to put a sharper focus ...
... belief that adolescent boys tend to take romance for a ... to heart matters, they might not be so fleeting after ... outside, an adolescent boy fails to communicate his emotions, leading ... ,Boys are more vulnerable and emotionally engaged in romantic ...
... journal Carcinogenesis show that exercise can offer protection against cancer. ... round the clock access to wheels took longer to develop ... a restricted diet had a healthy effect on mice by ... first study exposed mice to ultraviolet B rays of the ...
Cached Medicine News:Health News:Statin Therapy in Patients with Acute Coronary Syndrome Improves Survival 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 2Health News:Teenage Boys More Vulnerable And Emotionally Engaged In Romantic Relationships 3
... A concentrated enzymatic cleanser ... semi-automated hematology instruments. It ... all Abbott CELL-DYN® hematology ... instruments. The shelf life ...
Streck-CD3500 Hemoglobin/Lyse is a lytic reagent for the quantitative determination of hemoglobin on the Abbott CELL-DYN® 3500 and 3700. The shelf life is two years from the date of manufacture....
Streck-Diluent III Plus is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 3000, 3500 and 3700. The shelf...
Streck-Diluent IIIA is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1700. The shelf life is one year f...
Medicine Products: